

31 January 2017

Minutes
ICH Management Committee Meeting
Geneva, Switzerland
13-16 November 2017

List of Management Committee Participants

ICH Management Committee Members Representatives

Ms. Lenita Lindström-Gommers	EC, Europe
Prof. Spiros Vamvakas	EC, Europe
Dr. Sabine Luik	EFPIA
Mr. Pär Tellner	EFPIA
Dr. Theresa Mullin (Chair)	FDA, US
Ms. Joan Wilmarth Blair	FDA, US
Ms. Pujita Vaidya	FDA, US
Ms. Catherine Parker	Health Canada, Canada
Dr. Celia Lourenco	Health Canada, Canada
Dr. Hironobu Hiyoshi	JPMA
Dr. Masafumi Yokota	JPMA
Dr. Toshiyoshi Tominaga (Vice-Chair)	MHLW/PMDA, Japan
Mr. Naoyuki Yasuda	MHLW/PMDA, Japan
Dr. Nobumasa Nakashima	MHLW/PMDA, Japan
Dr. Peter K. Honig	PhRMA
Mr. Jerry Stewart	PhRMA
Dr. Petra Doerr	Swissmedic, Switzerland
Ms. Cordula Landgraf	Swissmedic, Switzerland

ICH Assembly Member Representative:

Dr. Tomas Salmonson	EC, Europe
---------------------	------------

ICH Management Committee Standing Observers Delegates:

Dr. David Jefferys	IFPMA
Dr. Sarah Adam	IFPMA
Dr. Gabriela Zenhäusern	WHO
Ms. Samuel Azatyan	WHO

ICH Management Committee Coordinators:

Dr. Georgios Balkamos	EC, Europe
Mr. Pär Tellner	EFPIA
Ms. Amanda Roache	FDA, US
Mr. Nick Orphanos	Health Canada, Canada
Mr. Mitsuo Mihara	JPMA
Mr. Fumihito Takanashi	MHLW/PMDA, Japan
Ms. Camille Jackson	PhRMA
Ms. Cordula Landgraf	Swissmedic, Switzerland

ICH Management Committee Technical Coordinators:

Dr. Milton Bonelli	EC, Europe
Dr. Michelle Limoli	FDA, US
Ms. Chieko Hirose	MHLW/PMDA, Japan

ICH Management Committee Additional Participants:

Dr. Agnès Saint-Raymond	EC, Europe
Mr. Martin Harvey	EC, Europe

Dr. Stephan Rönninger
Ms. Machiko Sumi
Ms. Erina Yamada
Dr. Yoshihiro Katsura

EFPIA
JPMA
JPMA
MHLW/PMDA, Japan

ICH Secretariat:

Dr. Véronique Kuntzelmann
Dr. Anne Latrive
Dr. Dawn Ronan

Table of Contents

Welcome & Adoption of the Agenda	5
A. Adoption of the Report of the Previous Teleconference.....	5
B. Implementation of ICH Guidelines.....	5
C. Opening-up of MC to Elected Representatives.....	6
D. Oversight of Working Groups.....	6
E. Financial Matters.....	8
F. Meetings.....	9
G. General Operational Matters	9
H. Membership and Observership Applications	10
I. Communication.....	10
J. Election of MC Chair and Vice-Chair	11
K. Training	11
L. Procedural Matters.....	12
M. New Topic Proposals and Strategic Discussions	12
N. Annual Work Plan and Multi-Annual Strategic Plan.....	14
O. WGs Meeting in Kobe, Japan.....	14
P. Press Release	15
Q. Dates of the next Meetings	16

ICH Management Committee Meeting

Minutes

Welcome & Adoption of the Agenda

Dr. Mullin (MC Chair, FDA, US) and Dr. Tominaga (MC Vice-Chair, MHLW/PMDA, Japan) welcomed MC Member Representatives and Standing Observer delegates and the agenda was adopted without modification.

A. Adoption of the Report of the Previous Teleconference

MC Actions/Decisions:

- The MC noted the MC minutes from the Montreal meeting held in May/June 2017, dated 1 September 2017;
- The MC noted the Report of the Coordinators teleconference held on 31 August 2017, dated 19 September 2017;
- The MC noted the Report of the MC Technical teleconference held on 25 September 2017, dated 26 October 2017;
- The MC noted the Report of the MC teleconference held on 6 September 2017, dated 26 September 2017;
- The MC noted the Report of the MC teleconference held on 26 September 2017, dated 13 October 2017;
- The MC noted the Report of the MC teleconference held on 3 October 2017, dated 2 November 2017;
- The MC noted the Report of the MC teleconference held on 17 October 2017, dated 23 October 2017;
- The MC adopted as final the Report of the MC teleconference held on 31 October 2017, dated 9 November 2017.

B. Implementation of ICH Guidelines

The MC noted the implementation table, maintained by the ICH Secretariat, which reflects the current state of play of the implementation of ICH Guidelines, based on the information provided by all Regulatory Members to the ICH Secretariat.

The Founding Industry Members presented a survey conducted amongst their members by a third-party regarding ICH Guideline implementation in their countries/regions of activity focused on the implementation of Tier 1 and Tier 2 ICH Guidelines across ICH Member and Observer countries/regions.

MC Actions/Decisions:

- The MC noted the outcome of the survey conducted by the Founding Industry Members regarding the implementation of Tier 1 and Tier 2 ICH Guidelines by ICH Members and Observers;

- The MC supported the presentation of the survey conducted by the Founding Industry Members to the Assembly;
- The MC supported the creation of an Implementation Subcommittee, to work in particular on the definition of the different levels of implementation, and potential metrics that could be used to monitor the implementation of ICH Guidelines;
- The MC agreed that the Implementation Subcommittee would work on defining the scope of an ICH-driven implementation survey using an independent third-party contractor;
- The MC supported that the Implementation Subcommittee would work with the ICH Secretariat on selecting an independent third-party provider for the implementation survey;
- The MC supported that as a next step the ICH Secretariat would invite nominations for the Implementation Subcommittee, noting that not all MC Members would need to be represented on the Subcommittee.

C. Opening-up of MC to Elected Representatives

The MC noted the applications received and the assessment summaries developed by the ICH Secretariat based on the information provided by the ICH Member applicants.

MC Actions/Decisions:

- The MC agreed on the need to clarify the notion of “good record of implementation” as stated in the Assembly Rules of Procedure 1.1.3. and Management Committee Rules of Procedure 2.2.1, with the MC agreeing to make a revision to the latter before the end of the year, in time for prospective applicants to review and prepare before the next ICH meeting in Kobe, Japan in June 2018;
- The MC agreed on postponing the organisation of the election of the Elected MC Representatives until the Kobe meeting in June 2018, in order to clarify the eligibility criteria and to inform the applicants of these criteria with sufficient time ahead of the meeting;
- The MC agreed to organise a teleconference before the end of the year to finalise revisions that would be made to the Management Committee Rules of Procedure 2.2.1 to clarify the interpretation of eligibility criteria with respect to the definition of a good record of implementation.

D. Oversight of Working Groups

IFPMA Participation

The MC was updated on the process agreed in Montreal in May/June 2017 to facilitate the participation of IFPMA National Industry Association experts in EWG/IWGs.

MC Action/Decision:

- The MC noted the process launched by IFPMA to facilitate the participation of IFPMA National Association experts in ICH WGs and that to-date five experts have been nominated in the following WGs: M9, M10, E8(R1), E19 and E11A.

Groups meeting in Geneva

- *E8(R1) informal Working Group: Revision on General Considerations for Clinical Trials*

MC Action/Decision:

- The MC endorsed the E8(R1) Concept Paper and Business plan and supported the establishment of an E8(R1) EWG.

- *Paediatric Extrapolation EWG*

MC Action/Decision:

- The MC agreed on the ICH code to be attributed to the Paediatric Extrapolation topic as E11A.

- *M2 EWG Electronic Standards for the Transfer of Regulatory Information (ESTRI)*

The MC was updated on the progress made by the group on strategic project opportunities, in particular the completion of the proposal for the Common Protocol Template, renamed CeSHarP - Clinical electronic Structured Harmonized Protocol, and the progress made on the proposal for the electronic Clinical Trial Application, renamed eCCTS – electronic Common Clinical Trial Submission, as well as the group's activities on project support for terminologies maintenance and data integrity guidance monitoring and on ESTRI.

MC Actions/Decisions:

- The MC supported the Concept Proposal on CeSHarP proposed by the M2 EWG and noted that, as the next step, a formal New Topic proposal would be submitted before the 15 December 2017 cut-off date for the New Topic proposal process;
- The MC supported that the M2 EWG would continue its work on the eCCTS project opportunity by performing a survey on regional processes for Clinical Trial Submissions and further complete a pre-concept paper including an overview on potential benefits and risks for regulators and industry based on expert input;
- The MC supported the finalisation of the PDF Specifications document and that it would be for Assembly endorsement in Geneva;
- The MC supported the plan of the M2 EWG for next activities on project opportunities, project support and ESTRI recommendations for the next 6 months, and noted that the plan would be for Assembly endorsement in Geneva.

- *E17 EWG: Multi-Regional Clinical Trials*

MC Action/Decision:

- Further to the adoption under *Step 4* by the Assembly of the E17 final Guideline, the MC agreed on the principle of converting the current E17 EWG to an IWG for training purposes;
- The MC tasked the E17 EWG to develop a Concept paper for an E17 IWG, with the Concept paper to include a more complete description of the work which would be undertaken, including Q&As, and an outline of the proposed training curriculum for presentation to the MC by early 2018 for approval.

- *Other Groups*

MC Action/Decision:

- The MC noted that the E19 Rapporteurship was for Assembly approval in Geneva.

Groups not meeting in Geneva

- *Q11 IWG: Q&As on Selection and Justification of Starting Materials for the Manufacture of Drug Substances*

MC Action/Decision:

- The MC supported Q11 IWG's proposal to develop training material.

- *Q12 EWG: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle management*

MC Action/Decision:

- The Regulatory Members of the MC agreed on the revised Q12 Technical Document integrating the additional text proposed by EC, Europe and that the revised Q12 Technical Document will be submitted to the ICH Assembly for adoption under *Step 2a* and for adoption as a draft guideline under *Step 2b* with a proposal for an extended period of regulatory public consultation. The MC took note that the Industry Members did not support the additional text in the Q12 Technical Document.

E. Financial Matters

The Lead of the Financial Subcommittee provided an update on the activities of the Financial Subcommittee and sought MC views on items including the revised 2018 ICH Budget for Assembly approval in Geneva and the development of a 5-Year ICH Budget Plan (2018-2022) including incorporation of: projected annual membership fees; cost to contract a Professional Conference Organiser (PCO); increased IT expenses for ICH websites; trademark registrations costs for the ICH logo; costs associated with a MC interim meeting; and costs associated to adding 1 FTE for the ICH Secretariat.

MC Actions/Decisions:

- The MC agreed on the proposal regarding ICH logo trademark registration;
- The MC agreed on the revised 2018 ICH budget to be presented to the Assembly, including: the additional website costs for upgrades; the ICH Secretariat travel costs to the interim MC meeting; and the costs related to trademark registration. Furthermore, the MC supported the addition of 1 FTE to the ICH Secretariat to account for the growing need for Secretariat support, particularly of training activities (see also Items G and K).

Organisation of future meetings

MC Actions/Decisions:

- The MC supported the recommendations made by the Financial Subcommittee to engage with a Professional Conference Organiser (PCO) for future ICH meeting organisation starting in June 2019;
- The MC supported the next steps of the process, namely that the ICH Secretariat, supported by the Lead of the Financial Subcommittee, would conduct interviews with the shortlisted companies and that a contract be finalised preferably ahead of the interim MC meeting in March 2018.

Interim MC meeting

MC Actions/Decisions:

- The MC agreed on the organisation of an interim meeting of the MC based on having New Topics as the standing agenda item, and agenda items of additional Subcommittees as required;
- The MC agreed that the March 2018 MC interim meeting would be focused on the New Topic Subcommittee discussion and other Subcommittee discussion as needed and that all MC Members would be represented at the MC interim meeting by at least one Representative;
- The MC agreed that each Subcommittee will perform its own activities and make decisions on recommendations to be presented to the full MC for decision shortly after the Interim meeting and that MC members in attendance should be prepared to represent the position of their organisations and have the authority to progress items for ultimate MC decision, or recommendation to the Assembly;
- The MC agreed further discussion was needed on the model of the interim MC meeting.

F. Meetings

Designation of June 2019 Meeting Location and Responsibility

MC Action/Decision:

- The MC supported that the June 2019 meeting take place in Europe and will be organised by the selected PCO, and noted that the location would be selected by the ICH Secretariat depending on the PCO's proposed options, with appropriate consultation of the MC on dates and the selected location.

Organisation of June 2018 & November 2018 ICH Meetings

MC Actions/Decisions:

- The MC acknowledged the report from JPMA that the organisation of the Kobe meeting to be held on 2-7 June 2018 is on track for a targeted number of 18 WGs, and that it would be possible to accommodate longer WGs meetings if necessary;
- The MC agreed that the November 2018 meeting will be held on 10-15 November in the U.S (location to be confirmed).

G. General Operational Matters

ICH Secretariat

The ICH Secretariat announced to the MC the completion on 10 November 2017 of the transfer of assets from IFPMA, as trustee of the former ICH (International Conference on Harmonisation) to the new ICH Association. The MC noted that the Secretariat needed still to undertake several administrative steps to fully operationalise the ICH Association and that the process was being initiated for the transfer of MedDRA trademarks with trademark authorities in the relevant countries. The MC also noted that the ICH Secretariat would need to relocate offices from IFPMA. The ICH Secretariat also updated the MC on the activities of the ICH Secretariat including: implementation of recent MC decisions and support of growth of ICH; approach for report development and clarification of rules; update regarding maintenance and development of the ICH and the ICH WGs websites; and provided an overview of the participation of current Members and Observers in ICH.

MC Actions/Decisions:

- The MC supported that the ICH Secretariat directly undertake the necessary steps to fully operationalise the ICH Association and relocate offices, with the Secretariat to consult the MC Chair and Vice Chair, and/or Assembly Chair and Vice Chair as considered necessary;
- The MC noted the current level of Secretariat support and the resource requirement related to the implementation and maintenance of Assembly and MC actions/decisions, and acknowledged the need to monitor Secretariat staffing needs in view of the growth of the workload associated with new Members and Observers, new tasks, and the operation of the independent legal entity (see also Items E and K);
- The MC acknowledged the need to adhere to the previously agreed-upon policies for efficiency in order to ensure a smooth running of ICH operations;
- The MC supported that the statistics on ICH Member and Observer participation in ICH WGs should be included in presentations on ICH, including the “Overview of ICH” slide-deck published on the ICH website and in the “Briefing session on ICH” for experts.

IPRF-IGDRP Consolidation

The IPRF Chair updated the MC on the work being undertaken regarding the arrangement to be put in place with ICH for the provision of Secretariat support services to the newly consolidated IPRF-IGDRP.

MC Action/Decision:

- The MC noted that the consolidated IPRF-IGDRP initiative would take effect as of 1 January 2018 under the new name IPRP (International Pharmaceutical Regulators Programme) and that the ICH Secretariat would begin the transition to providing services to IPRP from 1 January 2018. The MC noted that support of IPRP activities will be conducted and financed separately from support of ICH activities.

H. Membership and Observership Applications

The Leads of the Membership Subcommittee provided an update on the activities of the Membership Subcommittee including an overview of applications received for Membership/Observership.

MC Actions/Decisions:

- The MC agreed to recommend the following Membership application to the Assembly for approval:
 - HSA, Singapore.
- The MC agreed to recommend the following Observership application under category 17.1(a) to the Assembly for approval:
 - INVIMA, Colombia.
- The MC agreed to recommend the Observership application from the Bill & Melinda Gates Foundation under category 17.1(d) to the Assembly for approval on the basis of the eligibility criteria applicable at the time the application was submitted.

I. Communication

The Lead of the Communication Subcommittee provided an update on the activities of the Communication Subcommittee including: the implementation of the ICH Transparency Policy; the Communication and Stakeholder Engagement Plan for 2017-2018; the development of a *GCP*

Stakeholder engagement plan; the proposed amendments to the Business Plan and Work Plan templates and the proposed policy on translation of the ICH Member logo (for MC approval under agenda item L. procedural Matters); and high-level considerations for webcasting of ICH Assembly meetings.

MC Actions/Decisions:

- The MC supported that the *GCP Stakeholder engagement plan* would be further revised by the Communication Subcommittee in close collaboration with the E8(R1) EWG and with inclusion of a quantitative assessment of the required ICH Secretariat staff time for support of the engagement activities being considered. An updated version of the plan will be presented to the MC for its approval ahead of presentation to the Assembly;
- The MC supported further assessment by the Communication Subcommittee of the proposal to webcast parts of the ICH Assembly meetings, with consideration of technical requirements and cost and that further discussion take place at the June 2018 meeting in Kobe, Japan;
- The MC supported the additional proposals of the Communication Subcommittee, including: Business plan and Work plan template amendments; ICH Member Logo translation guidance; publication of MedDRA MC, Coordinators and Secretariat short biographies and photos on the ICH website; continued implementation of the 2017-18 Communications and Stakeholder Engagement Plan and development of a plan for 2018-19, which would be for MC approval and presentation to the Assembly at the June 2018 meeting;
- The MC supported that the ICH Secretariat proceed with the implementation of a web statistics and analytical tool for the ICH website.

J. Election of MC Chair and Vice-Chair

The MC noted the names of the persons nominated by the Founding Regulatory, Founding Industry and Standing Regulatory Members to be elected as Chair and Vice-Chair of the MC. The current MC Chair confirmed that these persons were eligible pursuant to the Article 37 (2) of the ICH Articles of Association which states that only the Permanent Regulatory Members of the MC are eligible to serve as Chair and Vice-Chair.

MC Action/Decision:

- Dr. Mullin (FDA, US) and Dr. Tominaga (MHLW/PMDA, Japan) were unanimously re-elected as MC Chair and Vice-Chair respectively, and will serve for a further one-year term.

K. Training

The Lead of the Training Subcommittee updated the MC on the activities of the Training Subcommittee, including the outcome of the ICH Training Pilot 2017 and the proposals for future training including financial considerations.

MC Actions/Decisions:

- The MC supported to continue to work with the training partners of the 2017 Pilot, according to the Revised Terms of Reference;
- The MC endorsed the eligibility criteria for training partners and the selection process;
- The MC agreed on the development of online training programmes;
- The MC supported continued focusing of the training strategy on the Tier 1 and Tier 2 (and closely related) ICH Guidelines for the new ICH Regulatory Members;
- The MC noted that the Training Subcommittee will develop a proposal on how to implement the agreed training strategy by March 2018;

- The MC supported the continued allocation of the budget for training purposes for the next 5 years, as already agreed in the 2018 ICH budget;
- The MC did not support using the ICH budget for the funding of travel for training programme participants;
- The MC supported the proposal that the Training Subcommittee would assist the WGs in the development of training material;
- The MC supported additional resources be allocated to the ICH Secretariat to account for the growing need for Secretariat support of the training activities, and agreed to add 1 FTE to enable the ICH Secretariat to support these activities in addition to other new activities assigned to the ICH Secretariat (see also Sections E and G above).

L. Procedural Matters

Standard Operating Procedures for ICH Working Groups

The Lead of the Standard Operating Procedure (SOP) for EWGs/IWGs Subcommittee reported on the revised version 4.0 of the SOP for EWGs/IWGs, including revisions to the Business Plan and Work Plan templates as well as to the EWG/IWG Assembly presentation template, and newly added text for clarification of rules related to: confidentiality; the official names of ICH Members and Observers; information published on the ICH website including the names and parties of experts of all ongoing WGs; the size of WGs; the role of Additional Expert; and the process for nomination of a Regulatory Chair.

MC Actions/Decisions:

- The MC approved version 4.0 of the SOP for EWGs / IWGs, dated 30 October 2017;
- The MC agreed that the SOP version 4.0 will be shared with the Assembly for information in Geneva and published on the ICH website;
- The MC supported the disbandment of the SOP Subcommittee, and agreed that the ICH Secretariat would follow up on any subsequent proposed changes to the SOP and coordinate directly with the MC for approval.

Management Committee Rules of Procedure

The ICH Secretariat presented the proposed changes to the MC Rules of Procedure (RoP) on granting the use of the ICH Member logo to third-party representative agencies of ICH Members and on the policy for the translation of the ICH Member logo.

MC Actions/Decisions:

- The MC approved the proposed revisions to the MC RoP on the use of the ICH Member logo by representative agencies of ICH Members and on the translation of the word “Member” in the ICH Member logo;
- The MC agreed that the revised MC RoP will be shared with the Assembly for information in Geneva and published on the ICH website.

M. New Topic Proposals and Strategic Discussions

Strategic Reflection Papers

The MC was updated on the comments received on the draft Vaccine Reflection Paper and on the draft Quality Reflection Paper on *Advancing Pharmaceutical Quality Standards*.

MC Actions/Decisions:

- The MC supported further work on the development of the reflection paper on Vaccines, and agreed on the need to refine the scope of the proposed position paper;
- The MC agreed that any further comments on the draft Quality Reflection Paper should be submitted by 15 December 2017;
- The MC supported giving further consideration to the creation of an *ad-hoc* Quality Discussion Group (DG) as proposed in the draft Quality Reflection Paper, with the MC still to consider the remit and participants of such a group. The DG would work to review the proposals set forth in the Quality Reflection Paper to prioritize work related to the further development of Quality Guidelines and the revision of existing outdated Quality Guidelines. This new DG would work by email and teleconference and would not meet face-to-face.

Suggestions for future strategic priorities

The MC was updated on proposals for future strategic priorities on Model Informed Drug Development (MIDD) and Patient Focused Drug Development (PFFD).

- The MC supported the development of a Reflection Paper on MIDD and a Reflection Paper on PFFD. The draft Reflection Papers should be developed with the aim of being circulated in the February timeframe in order to facilitate discussion at the planned interim MC meeting, and at the meeting in Kobe, Japan in June 2018;
- The MC agreed to develop a Strategic Topic Framework to build upon MC discussions held in Osaka in November 2016 for further MC discussion.

Processes for New Topics, Reflection Papers and Strategic Discussions

The Lead of the New Topics Subcommittee provided an update on the process for the selection of New Topics proposals integrated with the process for Reflection Papers and Strategic Discussions and the associated timelines.

MC Actions/Decisions:

- The MC supported the updated process for the submission and selection of new topics for harmonisation, including the following timelines: the capacity for new topics to start is determined in September-October by the MC; the deadline for submission of New Topic proposals is set on 15 December 2017 for all ICH Members and Observers; the circulation of proposals to the Assembly during December; the MC New Topics Subcommittee Q&A teleconferences (with Experts) between 15 January and 15 February 2018; the MC New Topics Subcommittee Interim meeting in March 2018 aiming to prioritize the New Topics proposals and making a recommendation in writing (a compilation of MC parties feedback submitted as part of the topic evaluation forms and amended based on the discussions held at the interim meeting) from the MC to the Assembly ahead of the June 2018 face-to-face meeting with the sharing of individual MC Member prioritisations to support Assembly discussions;
- The MC supported that the ICH Secretariat will conduct the following polls:
 - Poll to identify 3 dates for New Topic Subcommittee teleconferences between 15 January and 15 February 2018;
 - Poll to identify the 2 days for the New Topic Subcommittee interim meeting out of the 3 possible dates: March 26, 27 & 28;
 - Poll to identify which other Subcommittees would be interested to meet in parallel/back-to-back with the New Topic Subcommittee meeting.

N. Annual Work Plan and Multi-Annual Strategic Plan

MC Action/Decision:

- The MC supported the 2018 Work Plan and Multi-Annual Strategic Plan for the Association and supported their circulation to the Assembly for approval and their subsequent publication on the ICH website.

O. WGs Meeting in Kobe, Japan

The MC discussed the requests made by EWGs/IWGs to meet face-to-face at the next ICH meeting in Kobe, Japan, on 2-7 June 2018 and made provisional planning.

MC Actions/Decisions:

- The MC agreed to finalise the list of EWGs/IWGs which will meet in Kobe in June 2018 at the latest at the Technical MC teleconference. This list will be made available to the Assembly and also on the ICH website following the teleconference;
- The MC supported the list of EWGs/IWGs already approved in Geneva by the MC to meet in Kobe in June 2018, and agreed that, if confirmed at the Coordinators teleconference, these EWGs/IWGs would then obtain the final approval to meet;
- The following table summarises MC preliminary considerations on EWGs/IWGs meeting.

List of 23 Current ICH Working Groups (as of 16 November 2017)		Meeting in Kobe (to be confirmed at Coordinators TC)	Not meeting	For decision at MC TC
Efficacy Groups	Standing Paediatric EWG		X	
	E2B(R3) EWG/IWG	✓ (5 days, including a joint meeting with		
	E8(R1) EWG	✓ (5 days Sunday-Thursday)		
	E9(R1) EWG	✓		
	E11A EWG	✓		
	E14/S7B DG			✓
	E17 IWG			✓
	E19 EWG	✓ (including a joint meeting with E8(R1))		
Multidisciplinary Groups	M1 PtC WG			✓
	M2 EWG	✓		
	M4Q(R1) IWG		X	
	M7(R2) EWG			✓
	M8 EWG/IWG	✓		
	M9 EWG			✓
	M10 EWG	✓ (5 days)		
Quality Groups	Q3C(R7) Maintenance EWG		X	
	Q3D(R1) Maintenance EWG			✓
	Q11 IWG		X	
	Q12 EWG			✓
Safety Groups	S1 (R1) EWG			✓
	S5(R3) EWG			✓
	S9 IWG		X	
	S11 EWG			✓

P. Press Release

MC Action/Decision:

- The MC noted the points proposed for communication in the press release, and that in line with the Assembly RoP, the press release should undergo MC tacit approval further to an express approval by the Assembly Chair.

